CLINICAL TRIALS PROFILE FOR ZANAFLEX

All Clinical Trials for ZANAFLEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00047580 ↗	Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe	Completed	Elan Pharmaceuticals	Phase 3	2002-06-01	This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride tablets) taken while in the fed state (just after a meal) and in the fasted state (before a meal) in patients with moderate to severe spasticity.
NCT00287157 ↗	Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)	Completed	Teva GTC	Phase 1	2006-12-01	Nightly administration of a unique, sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve sleep and next-day functioning in CP (cerebral palsy) patients. It is hypothesized that this improvement in sleep efficiency (i.e.,fewer wake episodes, longer time asleep, etc.) with resulting improvement in quality-of-life (i.e.,improvements in next-day functioning, cognition and movement) may also be seen in a similar patient population, i.e., children with traumatic brain injury (TBI).
NCT00358293 ↗	Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity	Completed	Teva GTC	Phase 1/Phase 2	2006-12-01	Nightly administration of 8 mg of a unique sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve next-day spasticity, about 12 hours following dosing in 20 multiple sclerosis (MS) patients. This improvement was statistically significant when compared to oral tizanidine dosing. The current study is being undertaken to see if increasing the dose to 12 mg once nightly will result in an even greater improvement, with a longer effect, i.e., next day improvement in spasticity both in the morning as well as in the late afternoon.
NCT00430196 ↗	BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity	Completed	Allergan	Phase 4	2003-12-01	In this study, we will compare BOTOX® versus Zanaflex ® for the treatment of muscle overactivity in the upper limb following stroke or brain traums. This is a critical step in the development of local intramuscular treatment for patients with muscle overactivity following an acute brain lesions, as opposed to the more classic oral treatments. This study will be a multicenter, randomized, prospective, parallel, double blind study that enrolls subjects at twelve sites (including Mt. Sinai) throughout the United States and Europe. The purpose of this study is to evaluate the safety and efficacy of BOTOX® compared to Zanaflex® in reducing upper limb muscle tone in post-stroke subjects, as well as evaluating changes in muscle tone-related disability and drug-therapy tolerance. This will be an 18 week study. Subjects are eligible if they have been medically stable with upper limb spasticity 6 months after their first stroke. Subjects will be randomized to one of three treatment groups: Treatment Group I - intramuscular BOTOX® plus oral placebo, Treatment Group II - intramuscular placebo plus oral Zanaflex®, Treatment Group III - intramuscular placebo plus oral placebo. The dose of BOTOX® will be at the discretion of the investigator with a maximum of 500 U per subject. The dose of the Zanaflex® will be 4mg/day to a maximum of 36mg/day. The study anticipates that 150 subjects will be enrolled to provide sufficient information to answer the primary objective of safety and efficacy of the study.
NCT00430196 ↗	BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity	Completed	Icahn School of Medicine at Mount Sinai	Phase 4	2003-12-01	In this study, we will compare BOTOX® versus Zanaflex ® for the treatment of muscle overactivity in the upper limb following stroke or brain traums. This is a critical step in the development of local intramuscular treatment for patients with muscle overactivity following an acute brain lesions, as opposed to the more classic oral treatments. This study will be a multicenter, randomized, prospective, parallel, double blind study that enrolls subjects at twelve sites (including Mt. Sinai) throughout the United States and Europe. The purpose of this study is to evaluate the safety and efficacy of BOTOX® compared to Zanaflex® in reducing upper limb muscle tone in post-stroke subjects, as well as evaluating changes in muscle tone-related disability and drug-therapy tolerance. This will be an 18 week study. Subjects are eligible if they have been medically stable with upper limb spasticity 6 months after their first stroke. Subjects will be randomized to one of three treatment groups: Treatment Group I - intramuscular BOTOX® plus oral placebo, Treatment Group II - intramuscular placebo plus oral Zanaflex®, Treatment Group III - intramuscular placebo plus oral placebo. The dose of BOTOX® will be at the discretion of the investigator with a maximum of 500 U per subject. The dose of the Zanaflex® will be 4mg/day to a maximum of 36mg/day. The study anticipates that 150 subjects will be enrolled to provide sufficient information to answer the primary objective of safety and efficacy of the study.

Clinical Trial Conditions for ZANAFLEX

Condition Name

Condition Name for ZANAFLEX
Intervention	Trials
Healthy	2
Muscle Spasticity	2
Shoulder Arthropathy	1
Shoulder Pain	1

Condition MeSH

Condition MeSH for ZANAFLEX
Intervention	Trials
Muscle Spasticity	4
Multiple Sclerosis	2
Sclerosis	1
Chronic Pain	1

Clinical Trial Locations for ZANAFLEX

Trials by Country

Trials by Country for ZANAFLEX
Location	Trials
United States	14
Israel	2
Canada	2

Trials by US State

Trials by US State for ZANAFLEX
Location	Trials
California	2
Texas	1
Rhode Island	1
Oregon	1
Oklahoma	1

Clinical Trial Progress for ZANAFLEX

Clinical Trial Phase

Clinical Trial Phase for ZANAFLEX
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for ZANAFLEX
Clinical Trial Phase	Trials
Completed	7
Recruiting	1
Enrolling by invitation	1

Clinical Trial Sponsors for ZANAFLEX

Sponsor Name

Sponsor Name for ZANAFLEX
Sponsor	Trials
Henry Ford Health System	2
Teva GTC	2
Dr. Reddy's Laboratories Limited	2

Sponsor Type

Sponsor Type for ZANAFLEX
Sponsor	Trials
Industry	7
Other	4
NIH	1

ZANAFLEX: Clinical Trial Status, Market Landscape, and Future Projections

Last updated: February 19, 2026

Zanaflex, a muscle relaxant approved for spasticity associated with multiple sclerosis (MS) and spinal cord injury (SCI), demonstrates a stable market presence with limited new clinical development. Patent expirations and generic competition are key factors influencing its future.

What is the current clinical trial status of Zanaflex?

As of Q4 2023, Zanaflex (tizanidine hydrochloride) is not actively participating in new Phase II or Phase III clinical trials for its primary indications. The drug is approved by the U.S. Food and Drug Administration (FDA) and is widely prescribed for the management of spasticity.

• FDA Approval Status: Approved for symptomatic relief of spasticity associated with multiple sclerosis. Also approved for spasticity resulting from neurological disorders, such as stroke or spinal cord injury.
• Ongoing Research: Post-marketing surveillance and observational studies may be in progress, but no significant interventional trials are publicly listed on clinicaltrials.gov for novel indications or formulations.
• Generic Availability: Zanaflex is available as a generic medication under the name tizanidine hydrochloride, manufactured by multiple pharmaceutical companies. This generic status significantly impacts the market dynamics.

What is the patent and exclusivity landscape for Zanaflex?

The original patents protecting Zanaflex have long expired, leading to a highly competitive generic market.

• Original Compound Patent: The basic patent for tizanidine hydrochloride has expired.
• Formulation Patents: Any patents related to specific formulations or methods of use have also largely expired or have been successfully challenged.
• Exclusivity Periods: Zanaflex, as a branded product, has exhausted its market exclusivity periods. This has allowed for the entry of generic competitors.
• Patent Litigation: No significant ongoing patent litigation is reported that would extend Zanaflex's market exclusivity. The focus has shifted from patent protection to market share defense against generics.

What is the current market size and competitive landscape for Zanaflex?

The market for spasticity treatments is substantial, but Zanaflex faces intense competition from both branded and generic alternatives, as well as non-pharmacological therapies.

• Market Size: The global spasticity market is estimated to be worth billions of dollars, driven by conditions like MS, SCI, stroke, and cerebral palsy. Precise figures for tizanidine hydrochloride alone are difficult to isolate due to generic competition but it represents a significant segment within the oral muscle relaxant category for spasticity.
• Key Competitors (Branded):
  • Baclofen (Lioresal)
  • Dantrolene (Dantrium)
  • Diazepam (Valium)
• Key Competitors (Generic):
  • Tizanidine hydrochloride (multiple manufacturers)
  • Baclofen (generic)
  • Diazepam (generic)
• Market Share: Zanaflex (tizanidine hydrochloride) maintains a significant share of the oral spasticity treatment market due to its efficacy, established safety profile, and affordability as a generic. However, it competes directly with generic baclofen, which is often considered a first-line therapy.
• Pricing: The availability of generic tizanidine hydrochloride has driven down prices, making it a cost-effective option for patients and healthcare systems. Branded Zanaflex pricing, if still offered by the original innovator, is not a significant market factor.

What are the projected market trends for Zanaflex?

The future trajectory of Zanaflex is primarily shaped by its generic status and the evolving treatment paradigms for spasticity.

• Continued Generic Dominance: Zanaflex will continue to be a significant player in the generic market for spasticity management. Its market share will be influenced by pricing strategies of generic manufacturers and formulary placement by payers.
• Impact of New Therapies:
  • Botulinum Toxin Injections: These are increasingly used for focal spasticity and represent a significant alternative to oral medications, particularly for severe cases.
  • Intrathecal Baclofen Pumps: These offer an option for severe, generalized spasticity but are invasive and costly.
  • Novel Oral Agents: While not directly competing with tizanidine, research into new mechanisms of action for spasticity could eventually introduce novel oral agents that might offer improved efficacy or fewer side effects, indirectly affecting tizanidine's market share.
• Healthcare Cost Containment: The emphasis on cost-effectiveness will favor generic options like tizanidine hydrochloride. Payers will likely continue to prioritize generic prescriptions to manage healthcare expenditures.
• Geographic Variations: Market penetration may vary by region, influenced by local prescribing patterns, reimbursement policies, and the availability of competing treatments. Emerging markets might see increased adoption of affordable generics.
• Regulatory Environment: Changes in regulatory guidelines for spasticity management or safety warnings could impact prescribing. However, tizanidine has a long history of use, and significant regulatory shifts are unlikely without new safety data.

What are the key drivers and challenges for Zanaflex?

Key Drivers:

• Established Efficacy and Safety Profile: Zanaflex has a well-documented history of effectiveness and a predictable side effect profile, making it a reliable choice for clinicians.
• Affordability: As a generic medication, tizanidine hydrochloride is significantly more affordable than branded alternatives or newer therapies, appealing to cost-conscious healthcare systems and patients.
• Broad Approval Indications: Its approval for spasticity in MS and SCI covers substantial patient populations.
• Ease of Administration: Oral tablet formulation is convenient for patients.

Key Challenges:

• Intense Generic Competition: The market is crowded with multiple generic manufacturers, leading to price erosion and limited profit margins for any single producer.
• Competition from Other Oral Agents: Generic baclofen remains a primary competitor, often with similar efficacy and cost.
• Rise of Non-Oral Therapies: Botulinum toxin and intrathecal therapies offer alternatives for specific patient needs and may capture market share from oral medications, especially in more severe cases.
• Side Effect Profile: While generally manageable, common side effects such as somnolence, dizziness, and dry mouth can limit patient adherence or necessitate dose adjustments.
• Limited Pipeline for New Indications: Without new clinical trials or approved indications, Zanaflex's market growth is constrained to its existing therapeutic space, primarily driven by patient volume and generic market dynamics.

Key Takeaways

Zanaflex, as tizanidine hydrochloride, is a mature product in the spasticity market, characterized by its generic status. Its established efficacy, safety, and affordability are key market drivers, ensuring its continued relevance. However, significant growth prospects are limited by intense generic competition and the increasing adoption of alternative treatments like botulinum toxin injections. The market's future for Zanaflex will be defined by pricing strategies of generic manufacturers, payer formularies, and the overall evolution of spasticity management approaches.

Frequently Asked Questions

1. Are there any new branded versions of Zanaflex in development?

No, there are no new branded versions of Zanaflex in active development for novel indications or improved formulations. The market has shifted to generic tizanidine hydrochloride.

2. What is the typical dosage range for Zanaflex?

Typical dosages range from 2 mg to 8 mg taken 3 to 4 times daily. The maximum recommended daily dose is generally 36 mg.

3. How does Zanaflex compare to baclofen in treating spasticity?

Both Zanaflex (tizanidine) and baclofen are alpha-2 adrenergic agonists used for spasticity. Clinical studies suggest comparable efficacy, with individual patient responses varying. Tizanidine may have a slightly different side effect profile, with some patients reporting less weakness compared to baclofen, while others experience more sedation or dry mouth.

4. What is the most common side effect associated with Zanaflex?

The most common side effects include somnolence (drowsiness), dizziness, dry mouth, and asthenia (weakness).

5. Will Zanaflex be effective for spasticity caused by conditions other than MS or SCI?

Zanaflex is approved for spasticity related to MS and SCI. While it may be used off-label for other neurological conditions causing spasticity, its efficacy and safety profile in those specific contexts are not as extensively documented by regulatory bodies.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from clinicaltrials.gov [2] National Institutes of Health. (n.d.). ClinicalTrials.gov. Retrieved from www.clinicaltrials.gov [3] Market Research Reports (Various Publishers). (Ongoing Analysis). Global Spasticity Market Analysis. (Specific report titles and publishers vary and are proprietary).